Arcutis Biotherapeutics(ARQT)
$27.53-0.85 (-3.00%)
ARQT
Arcutis Biotherapeutics financials statements
$27.53
At close:-0.85 (-3.00%)
Want to see ARQT full AI Analyst Report?
Arcutis Biotherapeutics (ARQT) Ratios
993 Followers
Arcutis Biotherapeutics Ratios
ARQT's free cash flow for Q3 2026 was $18.80M. For the 2026 fiscal year, ARQT's free cash flow was decreased by $-97.00K and operating cash flow was $18.90M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 3.17 | 4.15 | 7.08 | 11.57 | 12.09 |
| Quick Ratio | 2.99 | 3.97 | 6.80 | 11.37 | 12.09 |
| Cash Ratio | 0.33 | 0.88 | 1.89 | 1.42 | 2.94 |
| Solvency Ratio | -0.05 | -0.72 | -1.03 | -1.29 | -1.86 |
| Operating Cash Flow Ratio | -0.04 | -1.38 | -5.29 | -6.82 | -5.24 |
| Short-Term Operating Cash Flow Coverage | -5.63 | 0.00 | 0.00 | -392.26 | -403.30 |
| Net Current Asset Value | $ 167.74M | $ 144.47M | $ 77.73M | $ 197.71M | $ 292.30M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.32 | 0.60 | 0.45 | 0.19 |
| Debt-to-Equity Ratio | 0.03 | 0.70 | 2.32 | 0.97 | 0.26 |
| Debt-to-Capital Ratio | 0.03 | 0.41 | 0.70 | 0.49 | 0.21 |
| Long-Term Debt-to-Capital Ratio | 0.03 | 0.40 | 0.69 | 0.49 | 0.20 |
| Financial Leverage Ratio | 2.29 | 2.21 | 3.85 | 2.14 | 1.37 |
| Debt Service Coverage Ratio | 0.05 | -4.06 | -7.76 | -18.06 | -474.81 |
| Interest Coverage Ratio | -1.01 | -4.73 | -8.11 | -19.27 | 0.00 |
| Debt to Market Cap | 0.00 | 0.06 | 0.90 | 0.24 | 0.07 |
| Interest Debt Per Share | 0.14 | 1.14 | 3.40 | 3.96 | 1.57 |
| Net Debt to EBITDA | -20.58 | -0.36 | -0.52 | -0.51 | 0.10 |
| Profitability Margins | |||||
| Gross Profit Margin | 90.24% | 90.27% | 91.63% | 79.54% | 0.00% |
| EBIT Margin | -0.77% | -57.10% | -384.72% | -8025.12% | 0.00% |
| EBITDA Margin | 0.47% | -55.78% | -381.56% | -7991.13% | 0.00% |
| Operating Profit Margin | -3.25% | -65.33% | -404.49% | -8183.04% | 0.00% |
| Pretax Profit Margin | -3.98% | -70.92% | -434.57% | -8449.76% | 0.00% |
| Net Profit Margin | -4.29% | -71.25% | -439.79% | -8449.76% | 0.00% |
| Continuous Operations Profit Margin | -4.29% | -71.25% | -439.79% | -8449.76% | 0.00% |
| Net Income Per EBT | 107.82% | 100.46% | 101.20% | 100.00% | 100.00% |
| EBT Per EBIT | 122.43% | 108.56% | 107.44% | 103.26% | 99.92% |
| Return on Assets (ROA) | -3.73% | -40.14% | -76.79% | -69.32% | -50.56% |
| Return on Equity (ROE) | -8.52% | -88.89% | -295.65% | -148.61% | -69.32% |
| Return on Capital Employed (ROCE) | -4.03% | -47.93% | -81.81% | -73.31% | -55.10% |
| Return on Invested Capital (ROIC) | -4.02% | -47.79% | -81.61% | -73.07% | -55.04% |
| Return on Tangible Assets | -3.86% | -41.26% | -78.27% | -70.45% | -50.56% |
| Earnings Yield | -0.44% | -8.31% | -117.10% | -38.24% | -20.14% |
| Efficiency Ratios | |||||
| Receivables Turnover | 2.57 | 2.69 | 2.31 | 0.44 | 0.00 |
| Payables Turnover | 2.93 | 1.35 | 0.42 | 0.09 | 0.10 |
| Inventory Turnover | 1.62 | 1.32 | 0.38 | 0.10 | 0.00 |
| Fixed Asset Turnover | 68.25 | 65.65 | 15.28 | 0.80 | 0.00 |
| Asset Turnover | 0.87 | 0.56 | 0.17 | 0.01 | 0.00 |
| Working Capital Turnover Ratio | 1.40 | 0.73 | 0.17 | 0.01 | 0.00 |
| Cash Conversion Cycle | 242.45 | 141.53 | 241.61 | 201.94 | -3517.49 |
| Days of Sales Outstanding | 141.92 | 135.69 | 158.03 | 837.54 | 0.00 |
| Days of Inventory Outstanding | 225.14 | 277.18 | 961.28 | 3637.41 | 0.00 |
| Days of Payables Outstanding | 124.61 | 271.35 | 877.70 | 4273.02 | 3517.49 |
| Operating Cycle | 367.06 | 412.88 | 1119.31 | 4474.95 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.04 | -0.93 | -3.56 | -4.68 | -3.53 |
| Free Cash Flow Per Share | -0.05 | -0.93 | -3.57 | -5.11 | -3.55 |
| Dividend Paid and CapEx Coverage Ratio | -8.20 | -784.32 | -577.24 | -11.07 | -175.50 |
| Capital Expenditure Coverage Ratio | -8.20 | -784.32 | -577.24 | -11.07 | -175.50 |
| Operating Cash Flow Coverage Ratio | -0.90 | -1.01 | -1.20 | -1.27 | -2.25 |
| Operating Cash Flow to Sales Ratio | -0.01 | -0.57 | -4.14 | -69.92 | 0.00 |
| Free Cash Flow Yield | -0.17% | -6.66% | -110.56% | -34.50% | -17.14% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -223.38 | -12.01 | -0.85 | -2.62 | -4.97 |
| Price-to-Sales (P/S) Ratio | 9.82 | 8.57 | 3.76 | 220.96 | 0.00 |
| Price-to-Book (P/B) Ratio | 19.50 | 10.70 | 2.52 | 3.89 | 3.44 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -585.47 | -15.00 | -0.90 | -2.90 | -5.83 |
| Price-to-Operating Cash Flow Ratio | -656.87 | -15.02 | -0.91 | -3.16 | -5.87 |
| Price-to-Earnings Growth (PEG) Ratio | 2.52 | 0.17 | 0.03 | -0.07 | -0.51 |
| Enterprise Value Multiple | 2055.19 | -15.73 | -1.50 | -3.27 | -4.88 |
| Enterprise Value | 3.66B | 1.72B | 341.37M | 963.38M | 1.00B |
| EV to EBITDA | 2055.19 | -15.73 | -1.50 | -3.27 | -4.88 |
| EV to Sales | 9.73 | 8.77 | 5.73 | 261.36 | 0.00 |
| EV to Free Cash Flow | -579.66 | -15.35 | -1.38 | -3.43 | -5.72 |
| EV to Operating Cash Flow | -650.35 | -15.37 | -1.38 | -3.74 | -5.75 |
| Tangible Book Value Per Share | 1.37 | 1.22 | 1.19 | 3.68 | 6.03 |
| Shareholders’ Equity Per Share | 1.49 | 1.30 | 1.28 | 3.81 | 6.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.08 | -0.00 | -0.01 | 0.00 | 0.00 |
| Revenue Per Share | 2.96 | 1.62 | 0.86 | 0.07 | 0.00 |
| Net Income Per Share | -0.13 | -1.16 | -3.78 | -5.66 | -4.18 |
| Tax Burden | 1.08 | 1.00 | 1.01 | 1.00 | 1.00 |
| Interest Burden | 5.19 | 1.24 | 1.13 | 1.05 | 1.00 |
| Research & Development to Revenue | 0.20 | 0.39 | 1.86 | 49.49 | 0.00 |
| SG&A to Revenue | 0.73 | 1.17 | 0.00 | 33.13 | 0.00 |
| Stock-Based Compensation to Revenue | 0.11 | 0.21 | 0.65 | 8.87 | 0.00 |
| Income Quality | 0.35 | 0.80 | 0.94 | 0.83 | 0.85 |
Currency in USD
